Categories
- Machine Tools: Cutting (3,917)
- Machine Tools: Metalforming, shearing, folding and punching (1,481)
- Machine Tools: moulding (1,058)
- Cutting tools (1,766)
- Welding and Joining (1,488)
- Finishing, preparation, coating and painting (1,025)
- Automation and assembly systems (1,044)
- Manufacturing support (8,593)
- Industry news, commerce, exhibitions, education (8,185)
- Packaging (2,865)
- Specialist Manufacturing Sectors and Metals Producing (1,318)
- Books, CDs and Videos (189)
- IT for manufacturing management and production (3,425)
- IT for engineering, industrial and commercial applications (4,837)
- Manufacturing IT hardware and communications (1,569)
- Used machinery and machine tools (29)
- Materials handling and storage (912)
- Wood and non-metallics working (73)
- Metrology instruments and systems (3,798)
- Testing and quality control systems and services (4,939)
- Subcontracting services (1,142)
Agreement joins analysis and diagnostics
A
LGC product story
Edited by the Manufacturingtalk editorial team
Jun 13, 2006
LGC and Gentris, a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions, have entered into a non-exclusive licensing agreement.
LGC, Europe's leading independent analytical laboratory, and Gentris, a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions, today announced that the companies have entered into a non-exclusive licensing agreement.
Under the terms of the agreement, Gentris obtains rights to make, use and sell diagnostic products and services which include testing for the CYP2D6*4 polymorphism in the US.
LGC is the exclusive licensor of this gene variation on behalf of Dundee University and Cancer Research UK.
Patients with the *4 variant of the CYP2D6 gene are known to be poor metabolisers of about 20 percent of commonly prescribed medications including painkillers, anti-depressants, analgesics and cardiovascular drugs.
The commercialization and adoption of CYP2D6 genetic testing services and diagnostic products will contribute to reducing adverse drug reactions (ADRs) in this population and improving the quality and efficacy of drugs and ultimately patient care.
Currently ADRs account for 106,000 deaths per year and 2.2 million hospitalizations per year in the US, making them the fourth leading cause of death and fifth leading cause of illness.
"The value of testing for key genetic markers associated with poor metabolism of medications has now become internationally accepted as a way to prevent some adverse drug reactions in individuals, and to identify those at risk of side effects," said Dr Paul Debenham, Director of Life Sciences at LGC.
"Today's advances in medical-based science and technology have generated DNA-based test technologies with the potential to shape the future care of us all.
We have seen a marked growth in the demand for pharmacogenetic services and products and are pleased to see a leading international provider like Gentris actively apply this exciting technology to the field." The licensing agreement with LGC is a key milestone for Gentris that demonstrates the company's commitment to building the industry's most robust and relevant portfolio of genetic testing services and diagnostic products.
"Gentris is dedicated to helping our clients integrate pharmacogenomic testing into their drug development programmes to deliver safer, more effective compounds to the market sooner," commented Gentris CEO Michael Murphy.
This announcement coincides with the recent release of Gentris' proprietary human genomic DNA reference controls for the CYP2D6 gene, which are currently available for research use.
No other commercial source of reference controls for the CYP2D6 gene is presently on the market.
Not what you're looking for? Search the site.
Contact LGC
Related Stories
